Macrophage secretome from women with HIV-associated neurocognitive disorders

Krystal Colon, Juliana Perez-Laspiur, Raymond Quiles, Yolanda Rodriguez, Valerie Wojna, Scott A. Shaffer, John Leszyk, Richard Skolasky, Loyda M. Melendez

Research output: Contribution to journalArticle

Abstract

Purpose: Thirty to 50% of HIV patients develop HIV-associated neurocognitive disorders (HANDs) despite combined antiretroviral therapy. HIV-1-infected macrophages release viral and cellular proteins that induce neuronal degeneration and death. We hypothesize that changes in the macrophage secretome of HIV-1 seropositive patients with HAND may dissect proteins related to neurotoxicity. Experimental design: Monocyte-derived macrophages (MDMs) were isolated from the peripheral blood of 12 HIV+ and four HIV- women characterized for neurocognitive function. Serum-free MDM supernatants were collected for protein isolation and quantification with iTRAQ® labeling. Protein identification was performed using a LTQ Orbitrap Velos mass spectrometer and validated in MDM supernatants and in plasma using ELISA. Results: Three proteins were different between normal cognition (NC) and asymptomatic neurocognitive disorders (ANI), six between NC and HIV-associated dementia (HAD), and six between NC and HAD. Among these, S100A9 was decreased in plasma from patients with ANI, and metalloproteinase 9 was decreased in the plasma of all HIV+ patients regardless of cognitive status, and was significantly reduced in supernatant of MDM isolated from patients with ANI. Conclusions and clinical relevance: S100A9 and metalloproteinase 9 have been associated with inflammation and cognitive impairment, and therefore represent potential targets for HAND treatment.

Original languageEnglish (US)
Pages (from-to)136-143
Number of pages8
JournalProteomics - Clinical Applications
Volume10
Issue number2
DOIs
StatePublished - Feb 1 2016

Fingerprint

Macrophages
HIV
AIDS Dementia Complex
Cognition
Metalloproteases
Proteins
Plasmas
HIV-1
Mass spectrometers
Design of experiments
Labeling
Viral Proteins
Neurocognitive Disorders
Blood
Research Design
Enzyme-Linked Immunosorbent Assay
Inflammation
Therapeutics
Serum

Keywords

  • HAND
  • ITRAQ
  • MMP9
  • S100A9
  • Secretome

ASJC Scopus subject areas

  • Clinical Biochemistry

Cite this

Colon, K., Perez-Laspiur, J., Quiles, R., Rodriguez, Y., Wojna, V., Shaffer, S. A., ... Melendez, L. M. (2016). Macrophage secretome from women with HIV-associated neurocognitive disorders. Proteomics - Clinical Applications, 10(2), 136-143. https://doi.org/10.1002/prca.201400203

Macrophage secretome from women with HIV-associated neurocognitive disorders. / Colon, Krystal; Perez-Laspiur, Juliana; Quiles, Raymond; Rodriguez, Yolanda; Wojna, Valerie; Shaffer, Scott A.; Leszyk, John; Skolasky, Richard; Melendez, Loyda M.

In: Proteomics - Clinical Applications, Vol. 10, No. 2, 01.02.2016, p. 136-143.

Research output: Contribution to journalArticle

Colon, K, Perez-Laspiur, J, Quiles, R, Rodriguez, Y, Wojna, V, Shaffer, SA, Leszyk, J, Skolasky, R & Melendez, LM 2016, 'Macrophage secretome from women with HIV-associated neurocognitive disorders', Proteomics - Clinical Applications, vol. 10, no. 2, pp. 136-143. https://doi.org/10.1002/prca.201400203
Colon K, Perez-Laspiur J, Quiles R, Rodriguez Y, Wojna V, Shaffer SA et al. Macrophage secretome from women with HIV-associated neurocognitive disorders. Proteomics - Clinical Applications. 2016 Feb 1;10(2):136-143. https://doi.org/10.1002/prca.201400203
Colon, Krystal ; Perez-Laspiur, Juliana ; Quiles, Raymond ; Rodriguez, Yolanda ; Wojna, Valerie ; Shaffer, Scott A. ; Leszyk, John ; Skolasky, Richard ; Melendez, Loyda M. / Macrophage secretome from women with HIV-associated neurocognitive disorders. In: Proteomics - Clinical Applications. 2016 ; Vol. 10, No. 2. pp. 136-143.
@article{da71fc2515b94891ab40ed53c084a236,
title = "Macrophage secretome from women with HIV-associated neurocognitive disorders",
abstract = "Purpose: Thirty to 50{\%} of HIV patients develop HIV-associated neurocognitive disorders (HANDs) despite combined antiretroviral therapy. HIV-1-infected macrophages release viral and cellular proteins that induce neuronal degeneration and death. We hypothesize that changes in the macrophage secretome of HIV-1 seropositive patients with HAND may dissect proteins related to neurotoxicity. Experimental design: Monocyte-derived macrophages (MDMs) were isolated from the peripheral blood of 12 HIV+ and four HIV- women characterized for neurocognitive function. Serum-free MDM supernatants were collected for protein isolation and quantification with iTRAQ{\circledR} labeling. Protein identification was performed using a LTQ Orbitrap Velos mass spectrometer and validated in MDM supernatants and in plasma using ELISA. Results: Three proteins were different between normal cognition (NC) and asymptomatic neurocognitive disorders (ANI), six between NC and HIV-associated dementia (HAD), and six between NC and HAD. Among these, S100A9 was decreased in plasma from patients with ANI, and metalloproteinase 9 was decreased in the plasma of all HIV+ patients regardless of cognitive status, and was significantly reduced in supernatant of MDM isolated from patients with ANI. Conclusions and clinical relevance: S100A9 and metalloproteinase 9 have been associated with inflammation and cognitive impairment, and therefore represent potential targets for HAND treatment.",
keywords = "HAND, ITRAQ, MMP9, S100A9, Secretome",
author = "Krystal Colon and Juliana Perez-Laspiur and Raymond Quiles and Yolanda Rodriguez and Valerie Wojna and Shaffer, {Scott A.} and John Leszyk and Richard Skolasky and Melendez, {Loyda M.}",
year = "2016",
month = "2",
day = "1",
doi = "10.1002/prca.201400203",
language = "English (US)",
volume = "10",
pages = "136--143",
journal = "Proteomics - Clinical Applications",
issn = "1862-8346",
publisher = "Wiley-VCH Verlag",
number = "2",

}

TY - JOUR

T1 - Macrophage secretome from women with HIV-associated neurocognitive disorders

AU - Colon, Krystal

AU - Perez-Laspiur, Juliana

AU - Quiles, Raymond

AU - Rodriguez, Yolanda

AU - Wojna, Valerie

AU - Shaffer, Scott A.

AU - Leszyk, John

AU - Skolasky, Richard

AU - Melendez, Loyda M.

PY - 2016/2/1

Y1 - 2016/2/1

N2 - Purpose: Thirty to 50% of HIV patients develop HIV-associated neurocognitive disorders (HANDs) despite combined antiretroviral therapy. HIV-1-infected macrophages release viral and cellular proteins that induce neuronal degeneration and death. We hypothesize that changes in the macrophage secretome of HIV-1 seropositive patients with HAND may dissect proteins related to neurotoxicity. Experimental design: Monocyte-derived macrophages (MDMs) were isolated from the peripheral blood of 12 HIV+ and four HIV- women characterized for neurocognitive function. Serum-free MDM supernatants were collected for protein isolation and quantification with iTRAQ® labeling. Protein identification was performed using a LTQ Orbitrap Velos mass spectrometer and validated in MDM supernatants and in plasma using ELISA. Results: Three proteins were different between normal cognition (NC) and asymptomatic neurocognitive disorders (ANI), six between NC and HIV-associated dementia (HAD), and six between NC and HAD. Among these, S100A9 was decreased in plasma from patients with ANI, and metalloproteinase 9 was decreased in the plasma of all HIV+ patients regardless of cognitive status, and was significantly reduced in supernatant of MDM isolated from patients with ANI. Conclusions and clinical relevance: S100A9 and metalloproteinase 9 have been associated with inflammation and cognitive impairment, and therefore represent potential targets for HAND treatment.

AB - Purpose: Thirty to 50% of HIV patients develop HIV-associated neurocognitive disorders (HANDs) despite combined antiretroviral therapy. HIV-1-infected macrophages release viral and cellular proteins that induce neuronal degeneration and death. We hypothesize that changes in the macrophage secretome of HIV-1 seropositive patients with HAND may dissect proteins related to neurotoxicity. Experimental design: Monocyte-derived macrophages (MDMs) were isolated from the peripheral blood of 12 HIV+ and four HIV- women characterized for neurocognitive function. Serum-free MDM supernatants were collected for protein isolation and quantification with iTRAQ® labeling. Protein identification was performed using a LTQ Orbitrap Velos mass spectrometer and validated in MDM supernatants and in plasma using ELISA. Results: Three proteins were different between normal cognition (NC) and asymptomatic neurocognitive disorders (ANI), six between NC and HIV-associated dementia (HAD), and six between NC and HAD. Among these, S100A9 was decreased in plasma from patients with ANI, and metalloproteinase 9 was decreased in the plasma of all HIV+ patients regardless of cognitive status, and was significantly reduced in supernatant of MDM isolated from patients with ANI. Conclusions and clinical relevance: S100A9 and metalloproteinase 9 have been associated with inflammation and cognitive impairment, and therefore represent potential targets for HAND treatment.

KW - HAND

KW - ITRAQ

KW - MMP9

KW - S100A9

KW - Secretome

UR - http://www.scopus.com/inward/record.url?scp=84956835956&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84956835956&partnerID=8YFLogxK

U2 - 10.1002/prca.201400203

DO - 10.1002/prca.201400203

M3 - Article

VL - 10

SP - 136

EP - 143

JO - Proteomics - Clinical Applications

JF - Proteomics - Clinical Applications

SN - 1862-8346

IS - 2

ER -